Clinical Research Directory

Inclusion Criteria: * Adults aged 18 years and older. * Patients receiving active systemic anticancer therapy with at least one of the following drug classes/regimens: * Taxanes (e.g., paclitaxel, docetaxel) breast cancer or ovarian cancer. * Neoadjuvant Pembrolizumab for stage III NSCLC * Ipilimumab + nivolumab neoadjuvant for stage III and first-line metastatic treatment for patients with PD-L1 \< 1% or asymptomatic brain metastases, or after progression on BRAF and MEK inhibitors in melanoma. * Nivolumab and Pembrolizumab in the adjuvant setting from stage IIB to stage III post-surgery in melanoma. * Adjuvant Nivolumab also in stage IV NED (No Evidence of Disease) in melanoma. * Ipilimumab in metastatic melanoma with progression on anti-PD1 therapy. * Pembrolizumab, Nivolumab and Atezolizumab for Metastatic Non-Small Cell Lung Cancer (NSCLC), breast cancer and gynecological cancer * Osimertinib: Adjuvant therapy in patients with common activating EGFR mutations for Non-Small Cell Lung Cancer (NSCLC) Amivantamab for advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC). * Pegylated liposomal doxorubicin for gynecological cancer * Presence at enrollment of clinically documented treatment-related dermatologic toxicity involving skin and/or hair and/or nails, defined as: • CTCAE v5.0 grade ≥1 for at least one pre-specified dermatologic event (e.g., rash, pruritus, xerosis, erythema, pigmentary alteration, photosensitivity, paronychia/onycholysis/nail dystrophy, alopecia) as assessed by the investigators and/or Dermatology-confirmed treatment-related toxicity when CTCAE categorization is not fully applicable (e.g., specific nail morphology patterns).Patients must have been on the current systemic regimen for ≥1 months and ≤12 months at the time of study entry. * Ability and willingness to undergo instrumental skin assessments under standardized conditions. * Patients who provide written informed consent Exclusion Criteria: * Pre-existing chronic dermatologic disease likely to confound assessment of treatment-related toxicity (e.g., psoriasis, atopic dermatitis/eczema, lupus, chronic urticaria), unless clinically inactive and deemed non-confounding by the investigator/dermatologist. * Active skin infection at the assessment site (bacterial, viral, fungal) that may alter barrier measures. * Any medical or dermatologic condition that, in the investigator's judgment, may confound assessment of treatment-related skin toxicity.